Why did NRXP's EPS remain flat throughout 2024?

NRX Pharmaceuticals' EPS remained flat throughout 2024 due to a combination of strategic financial management and operational focus:

1. Strategic Financial Moves: NRX Pharmaceuticals successfully reduced its net operating losses by 74% in Q3 2024 compared to the previous year, indicating a significant improvement in financial efficiency. This reduction in losses was primarily attributed to a decrease in research and development expenses and general and administrative expenses. The company also secured additional financing in January 2025, which provided the necessary capital to support its drug development initiatives and retire toxic debt.
2. Operational Focus on Drug Development: NRX Pharmaceuticals has been advancing its lead drug candidates, NRX-101 and NRX-100, with anticipated FDA decision dates by June 2025. The company's focus on drug development and preparation for NDA filings likely necessitated maintaining a relatively stable EPS to balance the need for continued research and development with the requirement for profitability in the near term.

In summary, NRX Pharmaceuticals' flat EPS in 2024 can be attributed to a strategic combination of financial management and operational focus on drug development.

1/3

NRXP Diluted EPS YoY, Diluted EPS